- Research article
- Open Access
Altered 5-HT2C receptor agonist-induced responses and 5-HT2C receptor RNA editing in the amygdala of serotonin transporter knockout mice
BMC Pharmacology volume 11, Article number: 3 (2011)
The serotonin 5-HT2C receptor (5-HT2CR) is expressed in amygdala, a region involved in anxiety and fear responses and implicated in the pathogenesis of several psychiatric disorders such as acute anxiety and post traumatic stress disorder. In humans and in rodent models, there is evidence of both anxiogenic and anxiolytic actions of 5-HT2C ligands. In this study, we determined the responsiveness of 5-HT2CR in serotonin transporter (SERT) knockout (-/-) mice, a model characterized by increased anxiety-like and stress-responsive behaviors.
In the three-chamber social interaction test, the 5-HT2B/2C agonist mCPP decreased sociability and sniffing in SERT wildtype (+/+) mice, both indicative of the well-documented anxiogenic effect of mCPP. This 5-HT2C-mediated response was absent in SERT -/- mice. Likewise, in the open field test, the selective 5-HT2C agonist RO 60-0175 induced an anxiogenic response in SERT +/+ mice, but not in SERT -/- mice. Since 5-HT2CR pre-mRNA is adenosine-to-inosine (A-to-I) edited, we also evaluated the 5-HT2CR RNA editing profiles of SERT +/+ and SERT -/- mice in amygdala. Compared to SERT +/+ mice, SERT-/- mice showed a decrease in less edited, highly functional 5-HT2C isoforms, and an increase in more edited isoforms with reduced signaling efficiency.
These results indicate that the 5-HT2CR in the amygdala of SERT -/- mice has increased RNA editing, which could explain, at least in part, the decreased behavioral responses to 5-HT2C agonists in SERT -/- mice. These alterations in 5-HT2CR in amygdala may be relevant to humans with SERT polymorphisms that alter SERT expression, function, and emotional behaviors.
The serotonergic system has been implicated in the pathophysiology and treatment of mood and anxiety disorders, as well as schizophrenia [1, 2]. The neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) influences neuronal activity via 14 5-HT receptors termed 5-HT1 through 5-HT7 (for a review, see ). The 5-HT2C receptor (5-HT2CR) has been implicated in normal and altered function of neural circuitries involved in these neuropsychiatric disorders via genetic, immunohistochemical and pharmacological approaches [2, 4, 5]. The 5-HT2CR is a G-protein coupled receptor (GPCR) coupled to PLC and PLA2, although additional signaling cascades have also been described [6–8].
Our previous work indicates that 5-HT transporter (SERT) knockout (-/-) mice are a valid model to study anxiety-related behaviors. These mice exhibit a complex phenotype dominated by anxiety, exaggerated stress responsiveness, and other physiological effects such as obesity and type 2 diabetes-like symptoms, all of which have been previously associated with 5-HT2CR genetic deficiencies ([9–12]; for a full review of SERT -/- mice, see ). Qu and colleagues  found a reduction in 5-HT2R-induced arachidonic acid release in multiple brain regions including the basolateral amygdaloid complex of SERT -/- mice [13, 14]. Further, we previously showed increased 5-HT2CR binding sites with no mRNA changes in the amygdala of SERT -/- mice compared SERT +/+ mice . The exact mechanisms responsible for the anxiety-like phenotype of SERT-/- mice are, however, not completely understood.
In humans and rodents, 5-HT2CR pre-mRNA is subject to adenosine-to-inosine (A-to-I) RNA editing [16, 17]. These base changes may result in an amino acid/protein different from those encoded by genomic DNA. It has been shown that RNA editing alters the G-protein efficiency of the 5-HT2CR and its intracellular downstream effects and interactions with both endogenous and exogenous receptor agonists, as well as desensitization mechanisms and constitutive activity [17–20]. It is noteworthy that the 5-HT2CR is the only example among the hundreds of GPCRs which exhibits this post-transcriptional processing .
A body of evidence suggests there are alterations in the 5-HT2CR editing pattern in patients with certain neuropsychiatric diseases, and it has been suggested that 5-HT2CR RNA editing may play a role in anxiety and depression [21–25]. The aim of the current study was to evaluate the status of 5-HT2CR-mediated anxiety-like behaviors in SERT -/- mice. The finding that SERT -/- mice were unresponsive to systemic administration of 5-HT2CR agonists at doses that elicited anxiogenic responses in SERT +/+ mice prompted us to further investigate the RNA editing profile of the 5-HT2CR in SERT -/- mice. We chose the amygdala as our primary target, since this region is critical in anxiety-related behaviors in rodents, non-human primates and humans [2, 26–28].
Social interaction test
In the social interaction test we first assessed "sociability" (the preference for spending time in the stranger side vs. the empty side) [main effects of side (F1,22 = 61.53, p < 0.0001); genotype (F1,22 = 0.92, N.S.) and drug (F1,22 = 1.72, N.S.); side × genotype interaction (F1,22 = 1.10, N.S.), side × drug interaction (F1,22 = 1.18, N.S.), genotype × drug interaction (F1,22 = 0.56, N.S.) and side × drug × genotype interaction (F1,22 = 6.87, p = 0.016)]. In vehicle-treated mice, there were no significant differences in sociability between SERT +/+ and -/- mice (Figure 1A). In SERT +/+ mice, administration of mCPP reduced sociability, indicative of its anxiogenic effect, whereas mCPP had no effect in SERT -/- mice, reflecting a diminished responsiveness of the 5-HT2CR (Figure 1A).
We next assessed "sniffing" (time spent sniffing the stranger cage vs. the empty cage) [main effects of side (F1,22 = 183.26, p < 0.0001), genotype (F1,22 = 5.59, p = 0.027) and drug (F1,22 = 8.97, p = 0.007); side × genotype interaction (F1,22 = 0.002, N.S.), side × drug interaction (F1,22 = 6.98, p = 0.015), genotype × drug interaction (F1,22 = 10.13, p = 0.004), and side × drug × genotype interaction (F1,22 = 11.61, p = 0.003)]. Vehicle-treated SERT +/+ and -/- mice both spent more time sniffing the stranger vs. the empty cage (Figure 1B). However, mCPP-treated SERT +/+ mice spent significantly less time sniffing the stranger cage compared to vehicle-treated SERT +/+ mice, whereas mCPP was without such an effect in SERT -/- mice (Figure 1B).
To rule out a possible role for changes in locomotor activity, we also assessed the number of entries to each side chamber [main effects of side (F1,22 = 28.23, p < 0.0001), genotype (F1,22 = 5.69, p = 0.026) and drug (F1,22 = 0.56, N.S.); side × genotype interaction (F1,22 = 0.20, N.S.), side × drug interaction (F1,22 = 0.03, N.S.), genotype × drug interaction (F1,22 = 0.56, N.S.), and side × drug × genotype interaction (F1,22 = 0.33, N.S.)]. There were no significant differences in the number of entries to the side chambers based on genotype or drug administration, suggesting that differences in locomotor activity did not play a role in the differences in anxiogenic responses elicited by mCPP in SERT +/+ mice (Figure 1C).
Administration of the selective 5-HT2CR antagonist RS 102221 15 min prior to mCPP blocked the anxiogenic effect of mCPP on sociability in wildtype C57BL/6J mice (Figure 2), confirming that the mCPP-induced anxiogenic response in the social interaction test was mediated by 5-HT2CR [main effects of side (F1,36 = 64.29, p < 0.0001) and drug (F3,36 = 0.64, N.S.); side × drug interaction (F3,36 = 6.43, p = 0.001). Neither RS 102221 nor mCPP, administered alone or in combination, affected locomotor activity (data not shown).
Open field test
To further explore this apparent reduction in responsiveness of 5-HT2CR observed in the social interaction test, we tested the effects of the 5-HT2C agonist RO 60-0175 in the open field test. For the frequency in the center of the open field, there was a significant main effect of genotype (F1,34 = 20.70, p < 0.0001), a significant main effect of drug condition (F1,34 = 9.75, p = 0.004) and a significant genotype × drug condition interaction (F1,34 = 4.78, p = 0.036). Following vehicle, SERT -/- mice made fewer visits to the center of the open field compared to SERT +/+ mice (Figure 3A). In SERT +/+ mice, treatment with RO 60-0175 decreased the frequency of visits to the center of the open field to levels observed in SERT -/- mice, suggestive of an anxiogenic effect, whereas RO 60-0175 had no effect in SERT -/- mice (Figure 3A). Regarding the total distance traveled, there was a significant main effect of genotype (F1,34 = 8.23, p = 0.007), a significant main effect of drug condition (F1,34 = 8.05, p = 0.008) and a significant genotype × drug condition interaction (F1,34 = 5.50, p = 0.025). At baseline, SERT -/- mice displayed less locomotor activity than SERT +/+ mice (Figure 3B). There was also a reduction in locomotion in SERT +/+ mice after RO 60-0175 administration, to levels comparable to SERT -/- mice; RO 60-0175 did not alter locomotion in SERT -/- mice. Activity in periphery, however, remained unchanged (data not shown).
Positively sequenced clones were used to compare the 5-HT2CR RNA editing profiles of SERT +/+ and -/- mice. The change in the editing rate at each specific editing site is shown in Figure 4A. Compared to SERT +/+ mice, SERT -/- mice had significant increases in the editing rate of site A (89.1% vs. 69.7%, p = 0.009), site B (84.2% vs. 65.9%, p = 0.0227) and site D (79.3% vs. 68.9%, p = 0.04). No differences in editing rates between the two SERT genotypes were found for sites C or E. The frequency of the RNA isoforms expressed at least 3% in one of the genotypes is shown in Figure 4B. Compared to SERT +/+ mice, SERT -/- mice evidenced a significant decrease in the expression of the non-edited (3.7% vs. 12.5%, p = 0.0003), D (3.7% vs.11.3%, p = 0.0117) and BD (4.6% vs.1.1%, p = 0.0356) isoforms. Further, two of the 5-HT2CR RNA isoforms were significantly increased in SERT -/- mice compared to SERT +/+ mice; ABD (42.2% vs.27.9%, p = 0.0012) and ABCD (23.4% vs. 17.1%, p = 0.016). Overall, this comparison of 5-HT2CR RNA editing profiles shows an increase in editing in SERT -/- mice vs. SERT +/- mice which results in a shift from non/low editing isoforms toward highly/full edited isoforms.
To our knowledge, the present data document the first assessments of anxiety-related behavioral alterations elicited by 5-HT2CR agonists in SERT -/- mice. Specifically, in the social interaction test, there were no significant differences in baseline assessments (vehicle administration) between SERT +/+ and SERT -/- mice. However, the anxiogenic response induced by the 5-HT2R agonist mCPP in SERT +/+ mice was absent in SERT -/- mice. The role of 5-HT2CR in this anxiogenic response was confirmed by pretreatment with the selective 5-HT2CR antagonist RS 102221, which blocked the anxiogenic effect of mCPP in wildtype C57BL/6J mice. Others have previously shown that both systemic and local (intra-amygdala) administration of mCPP increases anxiety levels in rodents, indicating that these receptors - possibly in the basolateral amygdala - are responsible for the anxiogenic effect of mCPP [29, 30].We also replicated previous findings from our lab showing that SERT -/- mice exhibit increased baseline anxiety-like behaviors in the open field test (for a review, see ). In addition, we showed that the anxiogenic response induced by the selective 5-HT2C agonist RO 60-0175 in the open field test in SERT +/+ mice is abolished in SERT -/- mice.
Using autoradiography to determine binding sites and in situ hybridization for mRNA content, previous reports from our lab indicate that 5-HT2CR mRNA levels are unaltered in amygdala of SERT -/- mice, whereas 5-HT2CR binding sites are significantly increased in this region . We therefore hypothesized that differences in RNA editing levels might account for this apparent discrepancy between levels of binding sites and the 5-HT2CR responsiveness to agonist stimulation. Given previous reports indicating that intra-amygdala injections of mCPP were able to elicit anxiogenic responses in rodents [29, 30], and the known role of this brain region in rodent and human anxiety, we focused our efforts on characterizing the RNA editing profile of 5-HT2CR in amygdala of SERT -/- mice compared to that of their SERT +/+ littermates.
SERT -/- mice had significantly decreased frequencies of non-edited, D and BD isoforms, as well as a significantly increased frequencies of the ABCD and ABD isoforms, the latter being the major isoform present in both SERT +/+ and -/- mice. ABCD codes for the VSV variant of the 5-HT2CR, and has been shown to exhibit reductions in receptor signaling both in agonist-elicited and intrinsic activity [16, 31]. The major isoform ABD codes for the variant VNV together with the AD isoform, which was slightly increased in SERT -/- mice compared to SERT +/+ mice. Previous studies also show that the VNV is the major 5-HT2CR isoform present in C57BL/6J mice [32, 33]. The VNV variant has reduced basal activity with no alteration in the potency of 5-HT stimulation [16, 31]. Thus, the present results suggest that SERT gene deletion shifts the RNA editing profile of the 5-HT2CR pre-mRNA population toward more edited, less active isoforms. This might explain the lack of effect of 5-HT2C agonists in both the social interaction and open field tests in SERT -/- mice at doses which were anxiogenic in SERT +/+ mice. It is important, however, to emphasize that the aforementioned reports indicating pharmacological differences among 5-HT2CR RNA editing isoforms were conducted with human and rat clones of each RNA isoform heterologously expressed, therefore caution is required when comparing the values from the present in vivo study conducted in mice [16, 31].
Previous reports have shown that pharmacological manipulations of serotonergic tone have an impact on 5-HT2CR RNA editing, either by direct 5-HT2CR activation by the non-selective 5-HT2 agonist DOI or by chronic fluoxetine (a selective serotonin reuptake inhibitor (SSRI)) treatment. Gurevich and colleagues  found that 129Sv mice treated with chronic fluoxetine exhibit significantly increased editing in site D and significantly decreased editing in site E. Chronic fluoxetine treatment in C57BL/6J mice, however, led to modest, non-significant changes in 5-HT2CR RNA editing, whereas the same treatment in BALB/c mice led to significant increases in editing of sites A, B, C and D . In SERT -/- mice, extracellular 5-HT levels are increased 3-6 fold in brain [1, 34]. Our current results suggest that, as a result of a targeted gene deletion of SERT, the increased extracellular levels of 5-HT alters 5-HT2CR RNA editing. In addition, these results suggest that targeted SERT gene deletion has a more profound impact than 28 days of treatment with fluoxetine in C57BL/6J wildtype mice . However, it is important to note that the prior studies analyzed 5-HT2CR RNA editing in forebrain neocortex [21, 22, 35], whereas the current study analyzed 5-HT2CR RNA editing in amygdala; thus, a direct comparison of these studies with the current studies is limited by the anatomical differences.
The observed increase in the frequency of 5-HT2CR RNA editing in SERT -/- mice might also explain the apparent paradoxical upregulation of the number of 5-HT2CR binding sites previously observed in SERT -/- mice . It has been shown that RNA editing also alters the ratio of alternative splicing variants, promoting the generation of the full mRNA variant coding for the functional protein in vitro, and recently in vivo. Thus, the increased RNA editing observed here in SERT -/- mice might be related to the previously observed increase in surface expression of 5-HT2CR . Another plausible link between RNA editing and 5-HT2CR upregulation is receptor desensitization . It is known that the non-edited 5-HT2CR isoform exhibits the highest constitutive activity and is present mainly intracellularly, whereas more edited isoforms are present largely as membrane-bound receptors and are more resistant to desensitization, at least in vitro[37, 38]. The observed increase in 5-HT2CR RNA editing in SERT -/- mice, which generates receptor isoforms with less efficacious signaling and reduced basal activity, is in line with previous findings of a reduction in DOI-induced arachidonic acid release in several brain regions, including the basolateral amygdaloid complex, in SERT -/- mice [13, 14]. However, the concomitant activation of 5-HT2A receptors does not allow a claim to be made for reduced activity of 5-HT2CR in those studies, especially as other signaling pathways for 5HT2CR receptors exist (e.g., PLC/IP3).
There is considerable evidence suggesting the involvement of 5-HT2CR in anxiety-related behaviors, although there is still debate about the precise role of this receptor in anxiety (for a review, see ). For example, it has been shown that activation of 5-HT2CR mediates the anxiogenic-like effects elicited by the non-selective 5-HT2C agonist mCPP in rodents, replicated in the current studies, and in humans [2, 39, 40]. Similarly, selective 5-HT2CR antagonists have been shown to exert anxiolytic effects in several animal models of anxiety in some reports [41, 42], but not in others [43, 44]. The current results are in line with reports of initial anxiogenic-like effects of SSRIs treatment in both humans and in several animal models of anxiety . The current data also show that, as indicated above, varying SERT expression can have profound consequences on the functional status of postsynaptic 5-HT2CR receptors, as expected from the marked increases in extracellular levels of 5-HT found in SERT -/- mice . These results also suggest that polymorphisms affecting SERT expression might exert a modulatory effect on the functional status of 5-HT2CR in humans. This might have implications for personalized medicine, as several selective 5-HT2CR agonists are being proposed as anti-obesity agents that have now advanced to clinical trials , in addition to the reported potential use of 5-HT2CR antagonists as anxiolytics .
The current studies focused on the analysis of RNA editing in amygdala, a key region involved in fear and anxiety. However, the circuit controlling anxiety-related traits and responses spans multiple regions. It will be of interest for future research to examine different brain areas to evaluate potential region-specific alterations in 5-HT2CR RNA editing frequencies, based on previous studies showing brain region-specific alterations in tissue 5-HT content, and in 5-HT synthesis and turnover rates [9, 47, 48]. A detailed characterization of the role of 5-HT2CR in amygdala control and in alterations in its RNA editing profile might also require a finer dissection (such as laser-caption microdissection) of the different subregions of the heterogeneous amygdala structure.
In summary, for the first time, we report functional alterations of 5-HT2CR-mediated responses to agonist stimulation in SERT -/- mice, as observed in the social interaction and open field paradigms. Further, we suggest that this alteration could be, at least in part, be explained by the significant increases in RNA editing of 5-HT2CR in the amygdala of SERT -/- mice that generates less active receptor isoforms. These findings will help to unravel the role of 5-HT neurotransmission in amygdala activity, especially in terms of alterations in SERT expression reported in humans with different alleles for the SERT promoter (5-HTTLPR s and l alleles) and other polymorphisms affecting SERT expression that have been found to be relevant in neuropsychiatric disorders [49–51]. Additional efforts are needed to further dissect the role of the 5-HT2CR among different amygdala subnuclei and in different neuronal types, to further understand the physiological relevance of 5-HT2CR editing in this and other brain regions, in addition to the role of 5-HT2CR in neuropsychiatric disorders.
Male SERT +/+ and -/- mice were originally produced by homologous recombination in ES cells as previously described , and are currently the product of ~20-24 heterozygous backcrosses with wildtype mice on a C57BL/6J genetic background. Commercial wildtype C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) were used for the antagonism experiment. The animals weighed ~20-35 g at the time of the experiments, and were housed in groups of 3-5 per cage with food and water available ad libitum. The animals were maintained on a 12-h light/dark cycle (lights on 0600 hours) in a facility approved by the American Association for Accreditation of Laboratory Animal Care. All experiments adhered to the guidelines of the National Institutes of Health, and were approved by the National Institute of Mental Health Animal Care and Use Committee.
Drugs and drug administration
The following compounds were used: (i) the 5-HT2B/2C agonist 1-(3-chlorophenly)piperazine (mCPP) (Tocris Bioscience, Ellisville, MO), (ii) the selective 5-HT2C agonist (αS)-6-Chloro-5-fluoro-α-methyl-1H-indole-1-ethanamine fumarate (RO 60-0175), and (iii) the selective 5-HT2C antagonist 8-[5-(2,4-Dimethoxy-5-(4-trifluoromethylphenylsulphonamido)phenyl-5-oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride (RS 102221) (Tocris Bioscience, Ellisville, MO). mCPP was administered at a dose of 1 mg/kg and RO 60-0175 was administered at a dose of 4 mg/kg, based on previous investigations that showed behavioral effects at these doses [29, 43] and preliminary pilot studies performed in our lab. RS 102221 was administered at 1 mg/kg based on previous investigations . mCPP and RO 60-0175 were dissolved in saline (sterile 0.9% NaCl solution), and RS 10221 was dissolved in 1% DMSO and saline. Drugs were injected via intraperitoneal (ip) injection (injection volume 10 ml/kg) 30 min prior to behavioral testing. In the antagonism study, RS 102221 was injected 15 min prior to mCPP.
A separate cohort of animals was used for each behavioral study. On test days, animals were moved in their home cage to a dimly lit testing room 1 h prior to experiments. All behavioral experiments were carried out between 1000 and 1400 hours.
Social interaction test
The social interaction test was used because it can detect the anxiolytic and anxiogenic effects of serotonergic agents [54, 55]. SERT +/+ and -/- mice were injected with either vehicle (saline) or mCPP. Thirty min later, mice were tested in an automated three-chamber box as described previously . Dividing walls had retractable doorways allowing access into each chamber. The automated box had photocells embedded in each doorway to allow quantification of the number of entries and the duration in each chamber of the social test box. The chambers of the apparatus were cleaned with water and dried with paper towels between each trial. At the end of each test day, the apparatus was sprayed with 70% ethanol and wiped clean with paper towels. The test has three 10-min phases: (1) Center habituation - the test mouse was first placed in the middle chamber and allowed to explore, with the doorways into the two side chambers closed; (2) Side chamber habituation - the mouse was allowed to explore the entire social test box, with the doorways into the two side chambers open, and (3) Sociability - after the second habituation period, the test mouse was enclosed in the center compartment of the social test box, and an unfamiliar mouse ("stranger," an adult C57BL/6J male) was enclosed in a wire cage (11 cm height, 10.5 bottom diameter, bars spaced 1 cm apart; Galaxy Cup; Spectrum Diversified Designs, Inc., Streetsboro, OH) and placed in a side chamber, and a similar empty wire cage was placed in the other side chamber. The location of the stranger alternated between the left and the right sides of the social test box between subjects. Following placement of the stranger mouse, the doors were reopened, and the subject was allowed to explore the entire social test box. The automated testing system recorded the amount of time spent and the number of entries in each chamber. In addition, the time spent sniffing each wire cage was recorded by an experimenter blind to the administered drug.
Open field test
As pilot studies indicated that a range of doses of mCPP (0 - 5 mg/kg) did not elicit anxiogenic effects in the open field test, we evaluated the effects of RO 60-0175, a selective 5-HT2CR agonist. SERT +/+ and -/- mice were injected with either vehicle or RO 60-0175. Thirty min later, mice were placed in the corner of a novel open field arena (40 × 40 × 35) and were allowed to explore for 5 min. Behaviors, including distance traveled (cm) and frequency of visits to center (20 × 20 cm), were recorded using the Noldus Ethovision Video Tracking system (Noldus Information Technology, Leesburg, VA).
Determinations of RNA editing profiles were performed in a separate cohort of SERT +/+ and -/- mice. Amygdala samples were obtained as previously described . Mice were sacrificed and brains were rapidly removed and placed in a brain block matrix. 1 mm coronal sections encompassing the amygdala region were dissected (posterior to the optic chiasm and anterior to the pons as ventral surface landmarks). From coronal sections, tissue containing visible amygdala nuclei was dissected using the rhinal sulcus as a guide. The tissues from both hemispheres were collected together.
Total RNA was extracted using miRvana PARIS Kit (Ambion, Austin, TX). 480 ng were used in first-strand cDNA synthesis using SuperScript III First-Strand SuperMix (Invitrogen, Carlsbad, CA) using the gene-specific primer CGGCGTAGGACGTAGATCGTTAAG . Amplification of the edited region was performed using primers sense (5'-TGTGCTATTTTCAACTGCGTCCATCATG), antisense (5'-CGGCGTAGGACGTAGATCGTTAAG) and Master Mix (Promega, Madison, WI). PCR products were cloned into pCR2.1 vector (Invitrogen, Carlsbad, CA) and used for transformation in E. coli. From each animal, isolated colonies were randomly chosen for plasmid DNA isolation (Qiagen, Valencia, CA) and bidirectionally sequenced with M13 primers at the National Institute of Neurological Disorders and Stroke (NINDS) intramural DNA sequencing core facility. Raw chromatograms from 60 positively sequenced colonies per animal (240 per genotype) were analyzed for changes in the editing region previously described.
For each experiment, data were analyzed using two-way (genotype × drug condition) or three-way (genotype × drug condition × side) analyses of variance (ANOVAs), or by t-tests when only two groups were compared. Post-hoc comparisons between genotypes or between drug conditions were conducted using t-tests. Significance was based on p < 0.05.
Murphy DL, Lesch KP: Targeting the murine serotonin transporter: insights into human neurobiology. Nat Rev Neurosci. 2008, 9 (2): 85-96. 10.1038/nrn2284.
Millan MJ: The neurobiology and control of anxious states. Prog Neurobiol. 2003, 70 (2): 83-244. 10.1016/S0301-0082(03)00087-X.
Fink KB, Gothert M: 5-HT receptor regulation of neurotransmitter release. Pharmacol Rev. 2007, 59 (4): 360-417.
Heisler LK, Pronchuk N, Nonogaki K, Zhou L, Raber J, Tung L, Yeo GS, O'Rahilly S, Colmers WF, Elmquist JK, et al.: Serotonin activates the hypothalamic-pituitary-adrenal axis via serotonin 2C receptor stimulation. J Neurosci. 2007, 27 (26): 6956-6964. 10.1523/JNEUROSCI.2584-06.2007.
Werry TD, Loiacono R, Sexton PM, Christopoulos A: RNA editing of the serotonin 5HT2C receptor and its effects on cell signalling, pharmacology and brain function. Pharmacol Ther. 2008, 119 (1): 7-23. 10.1016/j.pharmthera.2008.03.012.
Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP: Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol. 1998, 54 (1): 94-104.
McGrew L, Chang MS, Sanders-Bush E: Phospholipase D activation by endogenous 5-hydroxytryptamine 2C receptors is mediated by Galpha13 and pertussis toxin-insensitive Gbetagamma subunits. Mol Pharmacol. 2002, 62 (6): 1339-1343. 10.1124/mol.62.6.1339.
Werry TD, Gregory KJ, Sexton PM, Christopoulos A: Characterization of serotonin 5-HT2C receptor signaling to extracellular signal-regulated kinases 1 and 2. J Neurochem. 2005, 93 (6): 1603-1615. 10.1111/j.1471-4159.2005.03161.x.
Fox MA, Jensen CL, French HT, Stein AR, Huang SJ, Tolliver TJ, Murphy DL: Neurochemical, behavioral, and physiological effects of pharmacologically enhanced serotonin levels in serotonin transporter (SERT)-deficient mice. Psychopharmacology (Berl). 2008, 201 (2): 203-218. 10.1007/s00213-008-1268-7.
Heisler LK, Chu HM, Tecott LH: Epilepsy and obesity in serotonin 5-HT2C receptor mutant mice. Ann N Y Acad Sci. 1998, 861: 74-78. 10.1111/j.1749-6632.1998.tb10175.x.
Nonogaki K, Strack AM, Dallman MF, Tecott LH: Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat Med. 1998, 4 (10): 1152-1156. 10.1038/2647.
Miller KJ: Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity. Mol Interv. 2005, 5 (5): 282-291. 10.1124/mi.5.5.8.
Qu Y, Villacreses N, Murphy DL, Rapoport SI: 5-HT2A/2C receptor signaling via phospholipase A2 and arachidonic acid is attenuated in mice lacking the serotonin reuptake transporter. Psychopharmacology (Berl). 2005, 180 (1): 12-20. 10.1007/s00213-005-2231-5.
Basselin M, Fox MA, Chang L, Bell JM, Greenstein D, Chen M, Murphy DL, Rapoport SI: Imaging elevated brain arachidonic acid signaling in unanesthetized serotonin transporter (5-HTT)-deficient mice. Neuropsychopharmacology. 2009, 34 (7): 1695-1709. 10.1038/npp.2008.227.
Li Q, Wichems CH, Ma L, Van de Kar LD, Garcia F, Murphy DL: Brain region-specific alterations of 5-HT2A and 5-HT2C receptors in serotonin transporter knockout mice. J Neurochem. 2003, 84 (6): 1256-1265. 10.1046/j.1471-4159.2003.01607.x.
Burns CM, Chu H, Rueter SM, Hutchinson LK, Canton H, Sanders-Bush E, Emeson RB: Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature. 1997, 387 (6630): 303-308. 10.1038/387303a0.
Niswender CM, Copeland SC, Herrick-Davis K, Emeson RB, Sanders-Bush E: RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J Biol Chem. 1999, 274 (14): 9472-9478. 10.1074/jbc.274.14.9472.
Wang Q, O'Brien PJ, Chen CX, Cho DS, Murray JM, Nishikura K: Altered G protein-coupling functions of RNA editing isoform and splicing variant serotonin2C receptors. J Neurochem. 2000, 74 (3): 1290-1300. 10.1046/j.1471-4159.2000.741290.x.
Price RD, Sanders-Bush E: RNA editing of the human serotonin 5-HT(2C) receptor delays agonist-stimulated calcium release. Mol Pharmacol. 2000, 58 (4): 859-862.
Berg KA, Clarke WP, Cunningham KA, Spampinato U: Fine-tuning serotonin2c receptor function in the brain: molecular and functional implications. Neuropharmacology. 2008, 55 (6): 969-976. 10.1016/j.neuropharm.2008.06.014.
Gurevich I, Tamir H, Arango V, Dwork AJ, Mann JJ, Schmauss C: Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron. 2002, 34 (3): 349-356. 10.1016/S0896-6273(02)00660-8.
Englander MT, Dulawa SC, Bhansali P, Schmauss C: How stress and fluoxetine modulate serotonin 2C receptor pre-mRNA editing. J Neurosci. 2005, 25 (3): 648-651. 10.1523/JNEUROSCI.3895-04.2005.
Dracheva S, Chin B, Haroutunian V: Altered serotonin 2C receptor RNA splicing in suicide: association with editing. Neuroreport. 2008, 19 (3): 379-382. 10.1097/WNR.0b013e3282f556d2.
Gardiner K, Du Y: A-to-I editing of the 5HT2C receptor and behaviour. Brief Funct Genomic Proteomic. 2006, 5 (1): 37-42. 10.1093/bfgp/ell006.
Bhansali P, Dunning J, Singer SE, David L, Schmauss C: Early life stress alters adult serotonin 2C receptor pre-mRNA editing and expression of the alpha subunit of the heterotrimeric G-protein G q. J Neurosci. 2007, 27 (6): 1467-1473. 10.1523/JNEUROSCI.4632-06.2007.
Oler JA, Fox AS, Shelton SE, Christian BT, Murali D, Oakes TR, Davidson RJ, Kalin NH: Serotonin transporter availability in the amygdala and bed nucleus of the stria terminalis predicts anxious temperament and brain glucose metabolic activity. J Neurosci. 2009, 29 (32): 9961-9966. 10.1523/JNEUROSCI.0795-09.2009.
Hariri AR, Drabant EM, Munoz KE, Kolachana BS, Mattay VS, Egan MF, Weinberger DR: A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry. 2005, 62 (2): 146-152. 10.1001/archpsyc.62.2.146.
Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D, Egan MF, Weinberger DR: Serotonin transporter genetic variation and the response of the human amygdala. Science. 2002, 297 (5580): 400-403. 10.1126/science.1071829.
Bagdy G, Graf M, Anheuer ZE, Modos EA, Kantor S: Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int J Neuropsychopharmacol. 2001, 4 (4): 399-408. 10.1017/S1461145701002632.
Campbell BM, Merchant KM: Serotonin 2C receptors within the basolateral amygdala induce acute fear-like responses in an open-field environment. Brain Res. 2003, 993 (1-2): 1-9. 10.1016/S0006-8993(03)03384-5.
Herrick-Davis K, Grinde E, Niswender CM: Serotonin 5-HT2C receptor RNA editing alters receptor basal activity: implications for serotonergic signal transduction. J Neurochem. 1999, 73 (4): 1711-1717. 10.1046/j.1471-4159.1999.731711.x.
Hackler EA, Airey DC, Shannon CC, Sodhi MS, Sanders-Bush E: 5-HT(2C) receptor RNA editing in the amygdala of C57BL/6J, DBA/2J, and BALB/cJ mice. Neurosci Res. 2006, 55 (1): 96-104. 10.1016/j.neures.2006.02.005.
Du Y, Davisson MT, Kafadar K, Gardiner K: A-to-I pre-mRNA editing of the serotonin 2C receptor: comparisons among inbred mouse strains. Gene. 2006, 382: 39-46. 10.1016/j.gene.2006.06.007.
Mathews TA, Fedele DE, Coppelli FM, Avila AM, Murphy DL, Andrews AM: Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression. J Neurosci Methods. 2004, 140 (1-2): 169-181. 10.1016/j.jneumeth.2004.05.017.
Gurevich I, Englander MT, Adlersberg M, Siegal NB, Schmauss C: Modulation of serotonin 2C receptor editing by sustained changes in serotonergic neurotransmission. J Neurosci. 2002, 22 (24): 10529-10532.
Flomen R, Knight J, Sham P, Kerwin R, Makoff A: Evidence that RNA editing modulates splice site selection in the 5-HT2C receptor gene. Nucleic Acids Res. 2004, 32 (7): 2113-2122. 10.1093/nar/gkh536.
Marion S, Weiner DM, Caron MG: RNA editing induces variation in desensitization and trafficking of 5-hydroxytryptamine 2c receptor isoforms. J Biol Chem. 2004, 279 (4): 2945-2954. 10.1074/jbc.M308742200.
Porter RH, Malcolm CS, Allen NH, Lamb H, Revell DF, Sheardown MJ: Agonist-induced functional desensitization of recombinant human 5-HT2 receptors expressed in CHO-K1 cells. Biochem Pharmacol. 2001, 62 (4): 431-438. 10.1016/S0006-2952(01)00677-3.
Silverstone PH, Rue JE, Franklin M, Hallis K, Camplin G, Laver D, Cowen PJ: The effects of administration of mCPP on psychological, cognitive, cardiovascular, hormonal and MHPG measurements in human volunteers. Int Clin Psychopharmacol. 1994, 9 (3): 173-178. 10.1097/00004850-199409000-00005.
Murphy DL, Mueller EA, Hill JL, Tolliver TJ, Jacobsen FM: Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers. Psychopharmacology (Berl). 1989, 98 (2): 275-282. 10.1007/BF00444705.
Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, Avenell KY, Stean T, Upton N, Bromidge S, et al.: SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology. 1997, 36 (4-5): 609-620. 10.1016/S0028-3908(97)00038-5.
Martin JR, Ballard TM, Higgins GA: Influence of the 5-HT2C receptor antagonist, SB-242084, in tests of anxiety. Pharmacol Biochem Behav. 2002, 71 (4): 615-625. 10.1016/S0091-3057(01)00713-4.
Nic Dhonnchadha BA, Bourin M, Hascoet M: Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety. Behav Brain Res. 2003, 140 (1-2): 203-214. 10.1016/S0166-4328(02)00311-X.
Jenck F, Moreau JL, Berendsen HH, Boes M, Broekkamp CL, Martin JR, Wichmann J, Van Delft AM: Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats. Eur Neuropsychopharmacol. 1998, 8 (3): 161-168. 10.1016/S0924-977X(97)00055-2.
Salchner P, Singewald N: 5-HT receptor subtypes involved in the anxiogenic-like action and associated Fos response of acute fluoxetine treatment in rats. Psychopharmacology (Berl). 2006, 185 (3): 282-288. 10.1007/s00213-005-0247-5.
Dutton AC, Barnes NM: Anti-obesity pharmacotherapy: Future perspectives utilising 5-HT2C receptor agonists. Drug Discovery Today: Therapeutic Strategies. 2006, 3 (4): 577-583. 10.1016/j.ddstr.2006.11.005.
Kim DK, Tolliver TJ, Huang SJ, Martin BJ, Andrews AM, Wichems C, Holmes A, Lesch KP, Murphy DL: Altered serotonin synthesis, turnover and dynamic regulation in multiple brain regions of mice lacking the serotonin transporter. Neuropharmacology. 2005, 49 (6): 798-810. 10.1016/j.neuropharm.2005.08.010.
Ren-Patterson RF, Cochran LW, Holmes A, Lesch KP, Lu B, Murphy DL: Gender-dependent modulation of brain monoamines and anxiety-like behaviors in mice with genetic serotonin transporter and BDNF deficiencies. Cell Mol Neurobiol. 2006, 26 (4-6): 755-780. 10.1007/s10571-006-9048-6.
Wendland JR, Moya PR, Kruse MR, Ren-Patterson RF, Jensen CL, Timpano KR, Murphy DL: A novel, putative gain-of-function haplotype at SLC6A4 associates with obsessive-compulsive disorder. Hum Mol Genet. 2008, 17 (5): 717-723. 10.1093/hmg/ddm343.
Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, Xu K, Arnold PD, Richter MA, Kennedy JL, et al.: Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet. 2006, 78 (5): 815-826. 10.1086/503850.
Murphy DL, Lerner A, Rudnick G, Lesch KP: Serotonin transporter: gene, genetic disorders, and pharmacogenetics. Mol Interv. 2004, 4 (2): 109-123. 10.1124/mi.4.2.8.
Bengel D, Murphy DL, Andrews AM, Wichems CH, Feltner D, Heils A, Mossner R, Westphal H, Lesch KP: Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice. Mol Pharmacol. 1998, 53 (4): 649-655.
Kuznetsova EG, Amstislavskaya TG, Shefer EA, Popova NK: Effect of 5-HT2C receptor antagonist RS 102221 on mouse behavior. Bull Exp Biol Med. 2006, 142 (1): 76-79. 10.1007/s10517-006-0296-8.
Gonzalez LE, Andrews N, File SE: 5-HT1A and benzodiazepine receptors in the basolateral amygdala modulate anxiety in the social interaction test, but not in the elevated plus-maze. Brain Res. 1996, 732 (1-2): 145-153. 10.1016/0006-8993(96)00517-3.
Overstreet DH, Knapp DJ, Moy SS, Breese GR: A 5-HT1A agonist and a 5-HT2c antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats. Psychopharmacology (Berl). 2003, 167 (4): 344-352.
Nadler JJ, Moy SS, Dold G, Trang D, Simmons N, Perez A, Young NB, Barbaro RP, Piven J, Magnuson TR, et al.: Automated apparatus for quantitation of social approach behaviors in mice. Genes Brain Behav. 2004, 3 (5): 303-314. 10.1111/j.1601-183X.2004.00071.x.
We thank Dr. Francesco Papaleo and Dr. Jackie Crawley for their help with the social interaction paradigm. We also thank James Nagle and Debbie Kauffman from the NINDS DNA sequencing core facility for their excellent technical assistance with sequencing the clones. This research was supported by the NIMH Intramural Research Program and a NARSAD Young Investigator Award to JRW.
PRM conceived, designed and supervised the experiments, analyzed and interpreted the data, and wrote the manuscript. MAF participated in the design of studies, performed the pilot studies, performed the statistical analysis for the behavioral section, and contributed significantly to the writing of the manuscript. CLJ carried out the cloning experiments. JLL carried out the social interaction test experiments. HTF carried out the open field test experiments. JRW participated in the design and execution of the molecular experiments and helped with the RNA editing sequence analysis. DLM supervised PRM's work, participated in the design and coordination of the experiments, and helped to write the manuscript. All authors read the manuscript, provided critical input, and approved the final manuscript.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Moya, P.R., Fox, M.A., Jensen, C.L. et al. Altered 5-HT2C receptor agonist-induced responses and 5-HT2C receptor RNA editing in the amygdala of serotonin transporter knockout mice. BMC Pharmacol 11, 3 (2011). https://doi.org/10.1186/1471-2210-11-3
- RNA editing